我们从MSigDB数据库中识别了涵盖火焰死亡、凋亡和坏死的PANoptosis通路基因集。我们分析了前列腺腺癌（PRAD）中PANoptosis通路的扰动和相互作用，包括基因突变、转录、甲基化和临床特征。通过构建一个PANoptosis标志，我们准确预测了PRAD患者的预后和免疫治疗反应。我们进一步探索了标志的分子特征和免疫学作用，将患者分为高和低评分组。值得注意的是，高评分组与更好的生存结果和免疫治疗反应，以及PANoptosis和HALLMARK通路中更高的突变频率和富集分数相关。PANoptosis标志还增强了整体抗肿瘤免疫力，促进了免疫细胞浸润，上调了免疫检查点调节因子，并揭示了PRAD的冷瘤特征。我们还根据PANoptosis标志确定了潜在的药物靶点。这些发现为PRAD患者的新预后标志和治疗靶点的确定铺平了道路。© 2023作者。

PANoptosis pathway gene sets encompassing pyroptosis, apoptosis, and necroptosis were identified from the MSigDB database. We analyzed the perturbations and crosstalk in the PANoptosis pathway in prostate adenocarcinoma (PRAD), including gene mutation, transcription, methylation, and clinical features. By constructing a PANoptosis signature, we accurately predicted the prognosis and immunotherapeutic response of PRAD patients. We further explored the molecular features and immunological roles of the signature, dividing patients into high- and low-score groups. Notably, the high-score group correlated with better survival outcomes and immunotherapeutic responses, as well as a higher mutation frequency and enrichment score in the PANoptosis and HALLMARK pathways. The PANoptosis signature also enhanced overall antitumor immunity, promoted immune cell infiltration, upregulated immune checkpoint regulators, and revealed the cold tumor characteristics of PRAD. We also identified potential drug targets based on the PANoptosis signature. These findings lead the way in identifying novel prognostic markers and therapeutic targets for patients with PRAD.© 2023 The Author(s).